Home » USA Broker Ratings » Mylan N.V. – Consenus Indicates Potential 33.8% Upside

Mylan N.V. – Consenus Indicates Potential 33.8% Upside

Mylan N.V. found using ticker (MYL) have now 16 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 35 and 18 calculating the mean target price we have 25.81. Now with the previous closing price of 19.29 this now indicates there is a potential upside of 33.8%. There is a 50 day moving average of 18.25 while the 200 day moving average is 18.85. The company has a market cap of $9,817m. You can visit the company’s website by visiting: http://www.mylan.com

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals; TB Alliance; Theravance Biopharma; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Join us on our new LinkedIn page

Follow us on LinkedIn